IFOM
  1. Home
  2. Research
  3. Technological Platforms
  4. Functional Genomics Screening
  5. Marisa Aliprandi

Functional Genomics Screening

Screening Genomico Funzionale

Marisa Aliprandi

Technician

Marisa Aliprandi began her career at the Mario Negri Institute in Milan, where she developed a strong interest in studying the molecular mechanisms of epilepsy. There, she learned to work with animal models and acquired a solid foundation in immunohistochemical techniques.

She later moved to IFOM, where she focused on the production of monoclonal antibodies, gaining in-depth knowledge of the entire process, from animal immunization to hybridoma characterization. Subsequently, she expanded her expertise by working on the production of recombinant proteins in mammalian cells and collaborating with various research groups on protein purification and crystallization.

She is currently part of the Functional Genomic Screening unit, where she leverages her extensive experience with human and stem cells to conduct large-scale CRISPR screens. In particular, she is responsible for defining, together with the collaborating researchers, the optimal conditions for performing the screens and overseeing their operational management.

Publications

Publications Pre-IFOM
  1. Rizzi M, Perego C, Aliprandi M, Richichi C, Ravizza T, Colella D, Veliskova J, Moshe S L, De Simoni M G, Vezzani A Glia activation and cytokine increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal development Neurobiol Dis 2003; 14: 494-503
  2. Vezzani A, Michalkiewicz M, Michalkiewicz T, Moneta D, Ravizza T, Richichi C, Aliprandi M, Mule F, Pirona L, Gobbi M, Schwarzer C, Sperk G Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y Neuroscience 2002; 110: 237-243
  3. Rizzi M, Caccia S, Guiso G, Richichi C, Gorter J A, Aronica A, Aliprandi M, Bagnati R, Fanelli R, D'Incalci M, Samanin R, Vezzani A Limbic seizures induce P-glycoprotein in rodent brain: Functional implications for pharmacoresistance J Neurosci 2002; 22: 5833-5839
  4. Moneta D, Richichi C, Aliprandi M, Dournaud P, Dutar P, Billard J M, Carlo A S, Viollet C, Hannon J P, Fehlmann D, Nunn C, Hoyer D, Epelbaum J, Vezzani A Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice Eur J Neurosci 2002; 16: 843-849
Publications IFOM
  1. Veggiani G, Ossolengo G, Aliprandi M, Cavallaro U, de Marco A. “ Single-domain antibodies that compete with the natural ligand fibroblast growth factor block the internalization of the fibroblast growth factor receptor 1” Biochem Biophys Res Commun. 2011 May 20;408(4):692-6
  2. Aliprandi M, Sparacio E, Pivetta F, Ossolengo G, Maestro R, de Marco A. “The availability of a recombinant anti-SNAP antibody in VHH format amplifies the application flexibility of SNAP-tagged proteins” J Biomed Biotechnol. 2010;2010:658954.
  3. Capasso P, Aliprandi M, Ossolengo G, Edenhofer F, de Marco A. “Monodispersity of recombinant Cre recombinase correlates with its effectiveness in vivo” BMC Biotechnol. 2009 Sep 11;9:80.
  4. Deflorian G, Cinquanta M, Beretta C, Venuto A, Santoriello C, Baldessari D, Pezzimenti F, Aliprandi M, Mione M, de Marco A. “Monoclonal antibodies isolated by large-scale screening are suitable for labeling adult zebrafish (Danio rerio) tissues and cell structures” J Immunol Methods. 2009 Jul 31;346(1-2):9-17
  5. Monegal A., Huang H., Ami D., Martinelli C., Aliprandi M., Capasso P., Francavilla C., Ossolengo G., de Marco A. “Immunological applications of single domain llama recombinant antibodies isolated from a large naïve library” Protein Engineering, Design, and Selection Protein Eng Des Sel. 2009 Apr;22(4):273-80
Marisa Aliprandi

Facility members

Giuseppina D'Alessandro, Head of Core Facility

Mario Cinquanta

Reference PI

Ylli Doksani